JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2002) 175, 727-733       DOI: 10.1677/joe.0.1750727
© 2002 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fasshauer, M
Right arrow Articles by Paschke, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fasshauer, M
Right arrow Articles by Paschke, R
Journal of Endocrinology, Vol 175, Issue 3, 727-733
Copyright © 2002 by Society for Endocrinology


Articles

Isoproterenol is a positive regulator of the suppressor of cytokine signaling-3 gene expression in 3T3-L1 adipocytes

M Fasshauer, J Klein, U Lossner, and R Paschke


SOCS (suppressor of cytokine signaling)-3 has recently been shown to be an insulin- and tumor necrosis factor (TNF)-alpha-induced negative regulator of insulin signaling. To further clarify a potential involvement of SOCS-3 in the development of insulin resistance, we measured differentiation-dependent SOCS-3 mRNA expression in 3T3-L1 adipocytes and studied its regulation by various hormones known to impair insulin signaling using quantitative real-time RT-PCR. There was a differentiation-dependent downregulation of SOCS-3 mRNA by 50% over the 9 day adipocyte differentiation course. Interestingly, besides insulin and TNF-alpha, chronic treatment of differentiated 3T3-L1 cells with 10 microM isoproterenol for 16 h stimulated SOCS-3 gene expression by about 3.5-fold. Furthermore, isoproterenol stimulated SOCS-3 mRNA expression in a dose-dependent manner with significant activation detectable at concentrations as low as 10 nM isoproterenol. Moreover, a strong 27- and 47-fold activation of SOCS-3 mRNA expression could be seen after 1 h of isoproterenol and GH treatment respectively. The stimulatory effect of isoproterenol could be almost completely reversed by pretreatment of 3T3-L1 cells with the beta-adrenergic antagonist propranolol. Finally, isoproterenol's action could be mimicked by stimulation of G(S)-proteins with cholera toxin and of adenylyl cyclase with forskolin and dibutyryl cAMP. Taken together, our results demonstrate a differentiation-dependent downregulation of SOCS-3 in adipocytes and suggest that SOCS-3 gene expression is stimulated by beta-adrenergic agents via activation of a G(S)-protein-adenylyl cyclase-dependent pathway. As SOCS-3 is a novel inhibitor of insulin signaling, the data support a possible role of this protein as a selectively regulated mediator of catecholamine-induced insulin resistance.


This article has been cited by other articles:


Home page
J EndocrinolHome page
S. Kralisch, J. Klein, U. Lossner, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes
J. Endocrinol., June 1, 2005; 185(3): R1 - R8.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. Rieusset, K. Bouzakri, E. Chevillotte, N. Ricard, D. Jacquet, J.-P. Bastard, M. Laville, and H. Vidal
Suppressor of Cytokine Signaling 3 Expression and Insulin Resistance in Skeletal Muscle of Obese and Type 2 Diabetic Patients
Diabetes, September 1, 2004; 53(9): 2232 - 2241.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Han, H. Inoue, L. C. Flowers, and N. Sidell
Control of COX-2 Gene Expression through Peroxisome Proliferator-Activated Receptor {gamma} in Human Cervical Cancer Cells
Clin. Cancer Res., October 1, 2003; 9(12): 4627 - 4635.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society for Endocrinology.